Overactive Bladder (OAB)
Conditions
Keywords
Overactive Bladder (OAB), Observational, Registry
Brief summary
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.
Detailed description
Subjects will complete a study specific survey questionnaire at Screening and the Month 1 through Month 6 visits. Subjects will be followed for 6 months.
Interventions
None listed
Sponsors
GlaxoSmithKline
Astellas Pharma Inc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject has overactive bladder as determined by their prescribing physician * Subject is currently receiving pharmacotherapy for overactive bladder * Subject is willing to comply with required protocol/study requirements
Exclusion criteria
* Subject has a history of a clinically significant illness or medical condition prior to screening that would preclude participation in the study * Male subjects with Lower Urinary Tract Symptoms (LUTS) or Bladder Outlet Obstruction (BOO)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in overactive bladder (OAB) medication/ treatment regimen | 6 months |
| Reason for change in OAB medication/treatment regimen | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Persistence of use of any OAB medication as reported by the Physician | 6 months | — |
| Change in OAB medication including discontinuation of OAB medication as reported by the Physician | 6 months | — |
| Subject reported efficacy | 6 months | Measured by the Subject Survey Questionnaire |
Outcome results
None listed